ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200-Day Moving Average of $5.02

ImmuCell Co. (NASDAQ:ICCC)’s stock price crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $5.02 and traded as high as $5.13. ImmuCell shares last traded at $5.02, with a volume of 3,187 shares changing hands.

ImmuCell Price Performance

The company has a quick ratio of 0.87, a current ratio of 2.73 and a debt-to-equity ratio of 0.42. The firm has a fifty day moving average price of $5.16 and a two-hundred day moving average price of $5.02. The stock has a market capitalization of $38.91 million, a P/E ratio of -6.69 and a beta of 0.59.

ImmuCell (NASDAQ:ICCC) last issued its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.15) earnings per share for the quarter. ImmuCell had a negative net margin of 33.05% and a negative return on equity of 21.79%. The company had revenue of $5.10 million for the quarter.

Institutional Investors Weigh In On ImmuCell

Several large investors have recently bought and sold shares of ICCC. Dimensional Fund Advisors LP increased its holdings in ImmuCell by 175.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 62,170 shares of the biotechnology company’s stock worth $381,000 after buying an additional 39,591 shares in the last quarter. Vanguard Group Inc. boosted its position in ImmuCell by 22.2% in the first quarter. Vanguard Group Inc. now owns 204,325 shares of the biotechnology company’s stock worth $1,972,000 after purchasing an additional 37,081 shares during the last quarter. Northern Trust Corp boosted its position in ImmuCell by 153.8% in the fourth quarter. Northern Trust Corp now owns 32,646 shares of the biotechnology company’s stock worth $166,000 after purchasing an additional 19,781 shares during the last quarter. Mission Wealth Management LP purchased a new position in ImmuCell in the third quarter worth about $53,000. Finally, Geode Capital Management LLC boosted its position in ImmuCell by 20.1% in the second quarter. Geode Capital Management LLC now owns 45,727 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 7,645 shares during the last quarter. 13.47% of the stock is currently owned by institutional investors.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.